Abstract 1757P
Background
Breast cancer is a crucially prevailing cancer among women. Early detection and diagnosis of breast cancer are very important for patient survival. This study was conducted to devise a cost-effective and robust community-based breast cancer screening programme for LMIC.
Methods
All enrolled participants will undergo breast thermogram (BT) using an AI-based Thermalytix test along with clinical breast examination (CBE) by trained health workers. Women found suspicious in either CBE/BT or both will undergo confirmatory tests using Sonomammography (US) and/or Mammography; biopsy, where warranted, will be done to confirm the diagnosis. All symptomatic and asymptomatic women aged above 35 years of age, willing to give written informed consent for study participation were included. Those who are pregnant or lactating, treated for any cancers of breast/thorax, active inflammatory disorders on the skin of the breast, breast implants that can hamper testing using a BT or CBE were excluded from this study. The primary study endpoint is to evaluate the effectiveness of combined modality testing for breast cancer detection in healthy women. The benefit of a combined modality of Thermogram and clinical breast examination (CBE) for cancer detection rate were evaluated.
Results
A total of 3030 (both symptomatic and asymptomatic women) were screened for breast cancers over a period of 6months (Oct 2022 to April 2023). Women residing within a 120square kilometre radius were screened. Patients who were detected with screen abnormality on a thermogram B- Score 4 and above were 561 (18.51%). Six hundred and forty-six subjects (21.3%) who had an abnormality on both thermogram and CBE were recalled for further investigations. Out of which 5 subjects were detected with biopsy-proven breast malignancy (3 were early-stage breast cancer and 2 had locally advanced breast cancer).
Conclusions
Dual modality screening tool improves cancer detection rates, and this demonstrates the efficacy of these tools for breast cancer screening. Thermalytix with its artificial intelligence-based scoring system can assist the health care worker in the detection of breast cancer at a community level.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Ravind.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1756P - Vizcan: A Swedish population-based study to address cancer outcomes using an interactive platform
Presenter: Anders Berglund
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23